Trial Radar AI
Clinical Trial NCT07485881 for Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer Recurrent is not yet recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View
Back to Search

18F-PSMA PET/CT Versus CT Alone in Assessment of Prostatic Cancer Patients 59

Not yet recruiting
Clinical Trial NCT07485881 is an observational study for Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer Recurrent and is currently not yet recruiting. Enrollment is planned to begin on May 1, 2026 and continue until the study accrues 59 participants. Led by Assiut University, this study is expected to complete by June 1, 2028. The latest data from ClinicalTrials.gov was last updated on March 20, 2026.
Brief Summary
To compare the diagnostic performance of 18-F PSMA PET/CT and CT alone in initial staging, assessment of therapy response, as well as evaluation of biochemical recurrence of prostatic cancer patients

The main question it aims to answer is:

Does 18-F PSMA PET/CT have a superior role over CT in evaluation of prostatic cancer patients?

Detailed Description
Prostate cancer represents the most frequently diagnosed malignancy in men worldwide and accounts for approximately 30% of all new male cancer diagnoses in 2025, with recent data highlighting a significant 3% annual increase in incidence rates, particularly in advanced-stage disease\[1\]. The accurate staging and restaging of prostate cancer (PCa) are critical for determining the optimal therapeutic approach, particu...Show More
Official Title

18F-PSMA PET/CT Versus CT Alone in Initial Staging, Assessment of Therapy Response and Evaluation of Biochemical Recurrence in Prostatic Cancer Patients

Conditions
Prostate CancerProstate Cancer MetastaticProstate Cancer Recurrent
Publications
Scientific articles and research papers published about this clinical trial:
Other Study IDs
  • 18F PSMA PET/CT
NCT ID Number
NCT07485881
Start Date (Actual)
2026-05-01
Last Update Posted
2026-03-20
Completion Date (Estimated)
2028-06
Enrollment (Estimated)
59
Study Type
Observational
Status
Not yet recruiting
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Comparing 18-F PSMA PET/CT and CT in evaluation of prostatic cancer patients
Comparison of diagnostic performance of 18-F PSMA PET/CT and CT in staging, assessment of therapy response and evaluation of biochemical recurrence
2 years
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Correlation between quantitative measures and other clinical, pathological and laboratory measures
Correlation between quantitative measures and tumor burden of 18-F PSMA PET/CT with clinical, pathological and laboratory data including serum PSA, and Gleason Score
2 years
Participation Assistant
Eligibility Criteria

Eligible Ages
Child, Adult, Older Adult
Eligible Sexes
Male

Patients with known prostate cancer referred for 18-F PSMA PET/CT study

  • Patients with claustrophobia
  • Patients refuse to do the scan
Assiut University logoAssiut University
Study Responsible Party
Maram Mostafa Shafeek, Principal Investigator, Dr. Maram Mostafa, Assiut University
Study Central Contact
Contact: Maram Shafeek, MSc, +201019050584, [email protected]
No location data.